Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Recurrent Multiple Myeloma · Refractory Multiple Myeloma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Contact: Principal Investigator (Madhav Dhodapkar, MBBS)
Study leads
Madhav Dhodapkar, MBBS
Principal Investigator
Fred Hutch/University of Washington Cancer Consortium